OWD
REGN icon

Osborn Williams & Donohoe’s Regeneron Pharmaceuticals REGN Stock Holding History

Osborn Williams & Donohoe’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-453
Closed -$178K – 579
2019
Q1 		$178K Buy
+453
New +$187K 0.02% 349

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Osborn Williams & Donohoe's REGN Position: Q2 2019 in Review

Osborn Williams & Donohoe sold out of Regeneron Pharmaceuticals (REGN) in Q2 2019, closing a stake of 453 shares — an estimated $178K sold.

Osborn Williams & Donohoe first reported a position in REGN in Q1 2019 and held it in 1 quarter. The position peaked at $178K in Q1 2019. 658 funds tracked by Wall St. Rank hold REGN as of Q2 2019.

  • Osborn Williams & Donohoe reported no remaining Regeneron Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Osborn Williams & Donohoe sold 453 Regeneron Pharmaceuticals shares in Q2 2019, an estimated $178K.
  • Osborn Williams & Donohoe first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 1 quarter.
  • Osborn Williams & Donohoe's Regeneron Pharmaceuticals position peaked at $178K in Q1 2019.
  • 658 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q2 2019, filed 26 Jul 2019.